Drug intelligence / Profile preview

RP01

Development stage: Phase 2
Lead developer: Resistentia Pharmaceuticals
Modality: Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Small Molecules

Overview

RP01 is a novel anti-IgE immunotherapy developed as a therapeutic vaccine for allergic diseases. It works by stimulating the immune system to produce antibodies against Immunoglobulin E (IgE), which is the key mediator of allergic reactions. These induced antibodies bind to IgE, blocking its ability to trigger allergic responses regardless of the allergen source (such as pollen, dust mites, foodstuffs, or pets). The drug has been investigated primarily for use in treating allergic reactions and asthma[1][2].

Targets

IgE (Immunoglobulin E)

Beyond the preview

Go deeper on RP01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RP01.

Explore the full profile